Literature DB >> 16524390

Transesophageal echocardiography impacts management and evaluation of patients with stroke, transient ischemic attack, or peripheral embolism.

Buddhadeb Dawn1, Abdul M A Hasnie, Norberto Calzada, Rita A Longaker, Marcus F Stoddard.   

Abstract

The relative impact of transesophageal echocardiography (TEE) on the management of patients with specific embolic events, namely nonhemorrhagic cerebrovascular accident (CVA), transient ischemic attack (TIA), or peripheral embolism is controversial. The impact of TEE in 234 adult subjects with CVA (n = 141), TIA (n = 59), or peripheral embolism (n = 34) was determined. TEE was diagnostic of a potential embolic source in 61%, 51%, and 62% of patients with CVA, TIA, and peripheral embolism, respectively (P = NS). TEE results changed medication or surgical treatment in 32%, 22%, and 32% of patients with CVA, TIA, and peripheral embolism, respectively (P = NS). Anticoagulation was started on the basis of TEE findings in 11%, 12%, and 18% of patients with CVA, TIA, and peripheral embolism, respectively (P = NS). In 77% of all patients, TEE findings confirmed as appropriate the empiric decision made prior to TEE, to anticoagulate (60%; 12/20) or not to anticoagulate (79%; 168/214). These data demonstrate that TEE findings have a significant and similar impact on the clinical management of patients with various types of potential embolism. Future studies addressing the effectiveness of treatment, guided by TEE findings, in the prevention of recurrent embolic events are needed.

Entities:  

Mesh:

Year:  2006        PMID: 16524390     DOI: 10.1111/j.1540-8175.2006.00195.x

Source DB:  PubMed          Journal:  Echocardiography        ISSN: 0742-2822            Impact factor:   1.724


  7 in total

Review 1.  The value of transesophageal echocardiography for embolic strokes of undetermined source.

Authors:  Aristeidis H Katsanos; Rohini Bhole; Alexandra Frogoudaki; Sotirios Giannopoulos; Nitin Goyal; Agathi-Rosa Vrettou; Ignatios Ikonomidis; Ioannis Paraskevaidis; Konstantinos Pappas; John Parissis; Athanassios P Kyritsis; Anne W Alexandrov; Nikos Triantafyllou; Marc D Malkoff; Konstantinos Voumvourakis; Andrei V Alexandrov; Georgios Tsivgoulis
Journal:  Neurology       Date:  2016-08-03       Impact factor: 9.910

2.  Transesophageal echocardiography screening in subjects with a first cerebrovascular ischemic event.

Authors:  Kate C Young; Curtis G Benesch
Journal:  J Stroke Cerebrovasc Dis       Date:  2010-09-02       Impact factor: 2.136

3.  Sex differences in stroke evaluations in the Ischemic Stroke Genetics Study.

Authors:  Thabele M Leslie-Mazwi; Thomas G Brott; Robert D Brown; Bradford B Worrall; Scott L Silliman; L Douglas Case; Michael R Frankel; Stephen S Rich; James F Meschia
Journal:  J Stroke Cerebrovasc Dis       Date:  2007 Sep-Oct       Impact factor: 2.136

4.  Atrial Septal Aneurysm may Cause In-Hospital Recurrence of Cryptogenic Stroke.

Authors:  Ayako Kuriki; Yuji Ueno; Yuki Kamiya; Takahiro Shimizu; Ryosuke Doijiri; Yohei Tateishi; Muneaki Kikuno; Yoshiaki Shimada; Hidehiro Takekawa; Eriko Yamaguchi; Masatoshi Koga; Masafumi Ihara; Kenjiro Ono; Akira Tsujino; Koichi Hirata; Kazunori Toyoda; Yasuhiro Hasegawa; Nobutaka Hattori; Takao Urabe
Journal:  J Atheroscler Thromb       Date:  2020-07-17       Impact factor: 4.928

5.  Is transesophageal echocardiography needed for evaluating tissue-based transient ischemic attack?

Authors:  Mohamed Al-Khaled; Björn Scheef; Toralf Brüning
Journal:  Neural Regen Res       Date:  2018-07       Impact factor: 5.135

6.  The effect of TEE on treatment change in patients with acute ischemic stroke.

Authors:  Polina Specktor; Sergey Yalonetsky; Yoram Agmon; Elliot Sprecher; Faten Haj Ali; Gregory Telman
Journal:  PLoS One       Date:  2020-12-03       Impact factor: 3.240

Review 7.  Diagnostic Yield of TEE in Patients with Cryptogenic Stroke and TIA with Normal TTE: A Systematic Review and Meta-Analysis.

Authors:  Shamik Shah; Preeti Malik; Urvish Patel; Yunxia Wang; Gary S Gronseth
Journal:  Neurol Int       Date:  2021-12-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.